Nat. Biotechnol. 26, 361–363 (2008); published online 7 April 2008; corrected after print 7 August 2008
In the version of this article initially published, in Table 1, page 362, Protelos was wrongly cited as strontium malonate; in fact, Protelos is the current brand name of strontium ranelate. Unlike strontium malonate, strontium ranelate is approved by the European Medicines Evaluation Agency (EMEA) for the treatment of post-menopausal osteoporosis and has been shown in published clinical trials to decrease the risk of vertebral, nonvertebral and hip fractures in post-menopausal osteoporosis. The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0408-361
Rights and permissions
About this article
Cite this article
Sheridan, C. Erratum: Can 'double blockbuster' strengthen Amgen's backbone?. Nat Biotechnol 26, 947 (2008). https://doi.org/10.1038/nbt0808-947c
Issue Date:
DOI: https://doi.org/10.1038/nbt0808-947c
